Health2 years ago
NCCN Adds Trastuzumab Delxtecan and Sacituzumab Gobitecan to Guidelines for HER2-Negative Breast Cancer
“Convincing” data support the use of trastuzumab deluxtecan in patients with HER2-low metastatic breast cancer and sacituzumab gobitecan in patients with triple-negative breast cancer or hormone...
Recent Comments